SIETES :: 93083 citas

Resultados de la búsqueda por VALOR DUDOSO REFINAR BÚSQUEDA

1.

Rai V. What is the evidence for the use of potassium permanganate for wound care?. Drug Ther Bull 2020;58:mayo. [Ref.ID 103653]

2.

Anónimo. Domperidona*: supresión de la indicación en pediatría y recordatorio de las contraindicaciones en adultos y adolescentes. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2020;Referencia: MUH (FV), 3/2020:24 de febrero. [Ref.ID 103639]

3.

Mathieson S, Lin C-WC, Underwood M, Eldabe S. Pregabalin and gabapentin for pain. BMJ 2020;369:28 de abril. [Ref.ID 103627]

4.

PM Group. Gilead’s remdesivir appears to fail in leaked COVID-19 trial data. PMLiVE 2020:24 de abril. [Ref.ID 103590]

5.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure F-X, Nicastri E, Oda R, et al.. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020:10 de abril. [Ref.ID 103581]

6.

Barnett ML. Opioid prescribing in the midst of crisis — Myths and realities. N Engl J Med 2020;382:19 de marzo. [Ref.ID 103579]

7.

Jefferson T, Jones M, Al Ansari LA, Bzaweer G, Beller E, Clark J, Conly J, Del Mar C, Dooley E, Ferroni E, Glasziou P, Hoffman T, Thorning S, van Driel M. Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 1 - Face masks, eye protection and person distancing: systematic review and meta-analysis. medRxiv 2020:30 de marzo. [Ref.ID 103573]

8.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al.. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020:18 de marzo. [Ref.ID 103564]

9.

Corbella J. Un fármaco antigripal, la nueva esperanza ante el coronavirus. La Vanguardia 2020:20 de marzo. [Ref.ID 103562]

10.

Mahase E. Esketamine for treatment resistant depression is not recommended by NICE. BMJ 2020;368:30 de enero. [Ref.ID 103542]

11.

Anónimo. Melatonin for jet lag. Drug Ther Bull 2020;58:enero. [Ref.ID 103526]

12.

Butler CC, van der Velden AW, Bongard E, Saville BR, Holmes J, Coenen S, Cook J, et al.. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet 2020;395:4 de enero. [Ref.ID 103501]

13.

Moncrieff J. Re: Esketamine for treatment resistant depression. Putting drug company interests over the public good. BMJ 2019;366:23 de septiembre. [Ref.ID 103196]

14.

Musso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2019;365:9 de abril. [Ref.ID 103085]

15.

Anónimo. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. U.S. Food and Drug Administration 2019:9 de abril. [Ref.ID 103084]

16.

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

17.

Anónimo. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. U.S. Food and Drug Administration 2019:1. [Ref.ID 103050]

18.

Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, for the VITAL Research Group. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 2019;380:3 de enero. [Ref.ID 102995]

19.

Hengartner MP. What is the threshold for a clinical minimally important drug effect?. BMJ Evidence-Based Medicine 2018;23:21 de noviembre. [Ref.ID 102912]

20.

Furukawa TA, Maruo K, Noma H, Tanaka S, Imai H, Shinohara K, Ikeda K, Yamawaki S, Levine SZ, Goldberg Y, Leucht S, Cipriani A. Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatr Scand 2018;137:junio. [Ref.ID 102911]